×
Kura Oncology Total Liabilities 2012-2025 | KURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Kura Oncology total liabilities from 2012 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Kura Oncology Total Liabilities 2012-2025 | KURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Kura Oncology total liabilities from 2012 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$218.6B
Amgen (AMGN)
$164.4B
Gilead Sciences (GILD)
$137B
Vertex Pharmaceuticals (VRTX)
$120.7B
Bristol Myers Squibb (BMY)
$97.7B
CSL (CSLLY)
$84.2B
GSK (GSK)
$75.8B
Regeneron Pharmaceuticals (REGN)
$60.6B
Alnylam Pharmaceuticals (ALNY)
$42.4B
Argenex SE (ARGX)
$35B
BioNTech SE (BNTX)
$26.8B
Royalty Pharma (RPRX)
$20.3B
Insmed (INSM)
$19.5B
Biogen (BIIB)
$18.7B
Illumina (ILMN)
$16.2B
Genmab (GMAB)
$14B
Genmab (GNMSF)
$13.8B
Incyte (INCY)
$13.3B
Moderna (MRNA)
$12.7B
Exelixis (EXEL)
$12.1B
BioMarin Pharmaceutical (BMRN)
$11.4B
QIAGEN (QGEN)
$11B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.1B
Exact Sciences (EXAS)
$9.4B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.3B
Bio-Techne Corp (TECH)
$8.3B
Legend Biotech (LEGN)
$8.1B
Roivant Sciences (ROIV)
$7.8B